Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • Thursday
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)Seeking Alpha • Monday
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: AnalystBenzinga • Monday
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen WrongInvestors Business Daily • Monday
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromePRNewsWire • Monday
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander diseasePRNewsWire • 07/18/24
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndromePRNewsWire • 07/08/24
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/25/24
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completedPRNewsWire • 06/25/24
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedemaPRNewsWire • 06/18/24
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedemaPRNewsWire • 05/31/24
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)PRNewsWire • 05/23/24
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisPRNewsWire • 05/16/24